Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
house dust mite allergy VLP vaccine
- Development stage
- Preclinical
- Lead developer
- AdaptVac
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The house dust mite allergy VLP vaccine is a preclinical-stage therapeutic vaccine being developed by AdaptVac for the treatment of house dust mite (HDM) allergy. The vaccine utilizes AdaptVac's proprietary capsid virus-like particle (cVLP) technology to display the major HDM allergens, Der p 1 and Der p 2, in a highly repetitive, multivalent format. This architecture is designed to mimic the structure of a virus, thereby triggering a robust immune response that can induce allergen-specific tolerance or produce neutralizing IgG antibodies. The goal of the therapy is to prevent the allergic cascade by intercepting allergens before they can cross-link IgE on the surface of mast cells and basophils, potentially offering a more effective and long-lasting alternative to traditional subcutaneous immunotherapy (SCIT).
- Other names
- HDM VLP vaccineDer p 1/Der p 2 VLP vaccinehouse dust mite allergy VLP vaccine
02
Targets
Der p 2 (Dermatophagoides pteronyssinus allergen 2)Der p 1 (Dermatophagoides pteronyssinus allergen 1)
Beyond the preview
Go deeper on house dust mite allergy VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on house dust mite allergy VLP vaccine.